Filament Health Corp. announced that it has successfully completed an export of PEX010, the Company's botanical psilocybin drug candidate, to Israel. The shipment is believed to be the first botanical psilocybin to be exported to Israel. Hadassah University Hospital will study PEX010 in a clinical trial examining the effects of psilocybin for treatment-resistant obsessive-compulsive disorder (TR-OCD) and treatment-resistant post-traumatic stress disorder (TR-PTSD).

There is little effective therapy for chronic PTSD and despite decades of research, therapeutic options at the chronic stage are mostly limited to rehabilitation and symptom relief,  resulting in substantial unmet need for a solution. Preliminary research into psychedelic-assisted psychotherapy for OCD has demonstrated a decrease in symptoms, pointing to the necessity for controlled proof of concept trials to further substantiate its safety and efficacy for TR-OCD. The clinical trial at Hadassah University Hospital is the 28th study globally that is investigating Filament's psilocybin drug candidate for 12 mental health conditions including opioid use disorder, alcohol use disorder, depression, and coma.

Filament has supplied PEX010 to clinical trials in Europe, Canada, and the United States, in addition to Israel.